Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q3 2020 · 10-Q
Revenue$2.94M$2.94M−79.7% vs Q3 2019 Net Income-$14.28M-$14.28MN/M vs Q3 2019 EPS Diluted-$0.26-$0.26N/M vs Q3 2019 Operating Income-$12,999,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$6,730,000N/M Margins · derivedOperating margin-442.3%−422.2 pt vs Q3 2019
Net margin-486.0%−468.1 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 4, 2020 · 35 d after period end